HRP20100209T1 - Makrociklički inhibitori virusa hepatitisa c - Google Patents
Makrociklički inhibitori virusa hepatitisa c Download PDFInfo
- Publication number
- HRP20100209T1 HRP20100209T1 HR20100209T HRP20100209T HRP20100209T1 HR P20100209 T1 HRP20100209 T1 HR P20100209T1 HR 20100209 T HR20100209 T HR 20100209T HR P20100209 T HRP20100209 T HR P20100209T HR P20100209 T1 HRP20100209 T1 HR P20100209T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- c6alkyl
- image
- hydrogen
- alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 2
- 241000711549 Hepacivirus C Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 15
- 239000001257 hydrogen Substances 0.000 claims abstract 13
- -1 C1-C6alkoxy Chemical group 0.000 claims abstract 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 5
- 229910003827 NRaRb Inorganic materials 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001204 N-oxides Chemical class 0.000 claims abstract 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims abstract 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims abstract 2
- 150000002825 nitriles Chemical group 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 206010054261 Flavivirus infection Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 229940127073 nucleoside analogue Drugs 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05107057 | 2005-07-29 | ||
EP06113097 | 2006-04-25 | ||
PCT/EP2006/064822 WO2007014927A2 (en) | 2005-07-29 | 2006-07-28 | Macrocyclic inhibitors of hepatitis c virus |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100209T1 true HRP20100209T1 (hr) | 2010-05-31 |
Family
ID=37708968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100209T HRP20100209T1 (hr) | 2005-07-29 | 2010-04-14 | Makrociklički inhibitori virusa hepatitisa c |
Country Status (32)
Country | Link |
---|---|
US (1) | US7659245B2 (xx) |
EP (1) | EP1912981B1 (xx) |
JP (1) | JP5230418B2 (xx) |
KR (1) | KR101083631B1 (xx) |
AP (1) | AP2585A (xx) |
AR (1) | AR057702A1 (xx) |
AT (1) | ATE455775T1 (xx) |
AU (1) | AU2006274866B2 (xx) |
BR (1) | BRPI0614153A2 (xx) |
CA (1) | CA2617103C (xx) |
CY (1) | CY1110008T1 (xx) |
DE (1) | DE602006011905D1 (xx) |
DK (1) | DK1912981T3 (xx) |
EA (1) | EA014188B1 (xx) |
ES (1) | ES2339702T3 (xx) |
GT (1) | GT200600343A (xx) |
HK (1) | HK1116488A1 (xx) |
HR (1) | HRP20100209T1 (xx) |
IL (1) | IL188320A (xx) |
ME (1) | ME01454B (xx) |
MY (1) | MY151026A (xx) |
NO (1) | NO20081075L (xx) |
NZ (1) | NZ564540A (xx) |
PE (1) | PE20070343A1 (xx) |
PL (1) | PL1912981T3 (xx) |
PT (1) | PT1912981E (xx) |
RS (1) | RS51227B (xx) |
SI (1) | SI1912981T1 (xx) |
SV (1) | SV2008002641A (xx) |
TW (1) | TWI387597B (xx) |
UY (1) | UY29704A1 (xx) |
WO (1) | WO2007014927A2 (xx) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
JP5248783B2 (ja) | 2004-01-30 | 2013-07-31 | メディヴィル・アクチエボラーグ | Hcvns−3セリンプロテアーゼインヒビター |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
PL1913015T3 (pl) | 2005-07-29 | 2014-04-30 | Janssen R&D Ireland | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
JO2768B1 (en) * | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
MY139923A (en) | 2005-07-29 | 2009-11-30 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
UA93990C2 (ru) | 2005-10-11 | 2011-03-25 | Интермюн, Инк. | Соединения и способ ингибирования репликации вируса гепатита c |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
MX2009000486A (es) | 2006-07-13 | 2009-01-27 | Achillion Pharmaceuticals Inc | Peptidos de 4-amino-4-oxobutanoilo como inhibidores de replicacion viral. |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2470568T3 (es) * | 2006-11-17 | 2014-06-24 | Janssen R&D Ireland | Inhibidores macroc�clicos del virus de la hepatitis C |
MX2009008271A (es) * | 2007-02-01 | 2009-08-12 | Tibotec Pharm Ltd | Procesos e intermediarios para la preparacion de un inhibidor de proteasa macrocilico del vhc. |
CA2677697A1 (en) * | 2007-02-08 | 2008-07-14 | Tibotec Pharmaceuticals Ltd. | Pyrimidine substituted macrocyclic hcv inhibitors |
ITMI20071616A1 (it) | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
JP2010540549A (ja) * | 2007-09-24 | 2010-12-24 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ウイルス複製阻害剤としての尿素含有ペプチド |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
US8426360B2 (en) * | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
US8263549B2 (en) | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
EP2226315A4 (en) | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-AMINOQUINAZOLINE DERIVATIVE |
US8372802B2 (en) | 2008-03-20 | 2013-02-12 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044023B2 (en) | 2008-05-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2527166T3 (es) | 2008-12-10 | 2015-01-21 | Achillion Pharmaceuticals, Inc. | Nuevos péptidos de 4-amino-4-oxobutanoílo como inhibidores de la replicación viral |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN104478868A (zh) * | 2009-02-27 | 2015-04-01 | 奥索-麦克尼尔-詹森药品公司 | Hcv大环抑制剂的无定形盐 |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
AU2010251949A1 (en) * | 2009-05-29 | 2011-12-08 | Syngenta Participations Ag | Substituted quinazolines as fungicides |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
JP2014506255A (ja) | 2010-12-30 | 2014-03-13 | エナンタ ファーマシューティカルズ インコーポレイテッド | フェナントリジン大環状c型肝炎セリンプロテアーゼ阻害剤 |
CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
IN2014MN01465A (xx) | 2011-12-28 | 2015-04-17 | Janssen R & D Ireland | |
CN104918912B (zh) * | 2012-10-15 | 2017-02-22 | 阿尔比马尔公司 | 2‑氨基‑4,6‑二甲氧基苯甲酰胺和其他苯甲酰胺化合物的合成方法 |
ES2613766T3 (es) | 2012-10-19 | 2017-05-25 | Bristol-Myers Squibb Company | Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
WO2014145507A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
US9085607B2 (en) | 2013-03-15 | 2015-07-21 | Achillion Pharmaceuticals, Inc. | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
CN100381440C (zh) | 2002-04-11 | 2008-04-16 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3-ns4蛋白酶的抑制剂 |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US20040180815A1 (en) * | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
EP1590442A4 (en) * | 2003-02-07 | 2007-07-18 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
WO2004094452A2 (en) * | 2003-04-16 | 2004-11-04 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
PE20050431A1 (es) * | 2003-09-22 | 2005-07-19 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c |
JP5248783B2 (ja) * | 2004-01-30 | 2013-07-31 | メディヴィル・アクチエボラーグ | Hcvns−3セリンプロテアーゼインヒビター |
CN101273038A (zh) * | 2005-07-29 | 2008-09-24 | 美迪维尔公司 | 丙型肝炎病毒的大环化合物抑制剂 |
PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
BRPI0614621A2 (pt) * | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | inibidores macrocìclicos de vìrus da hepatite c |
US8012939B2 (en) * | 2005-07-29 | 2011-09-06 | Tibotec Pharmaceuticals Ltd. Co | Macrocyclic inhibitors of hepatitis C virus |
-
2006
- 2006-07-26 PE PE2006000903A patent/PE20070343A1/es not_active Application Discontinuation
- 2006-07-28 RS RSP-2010/0183A patent/RS51227B/sr unknown
- 2006-07-28 NZ NZ564540A patent/NZ564540A/en not_active IP Right Cessation
- 2006-07-28 PT PT06764268T patent/PT1912981E/pt unknown
- 2006-07-28 US US11/995,900 patent/US7659245B2/en not_active Expired - Fee Related
- 2006-07-28 ME MEP-2012-119A patent/ME01454B/me unknown
- 2006-07-28 GT GT200600343A patent/GT200600343A/es unknown
- 2006-07-28 KR KR1020087004894A patent/KR101083631B1/ko not_active IP Right Cessation
- 2006-07-28 PL PL06764268T patent/PL1912981T3/pl unknown
- 2006-07-28 TW TW095127585A patent/TWI387597B/zh not_active IP Right Cessation
- 2006-07-28 ES ES06764268T patent/ES2339702T3/es active Active
- 2006-07-28 JP JP2008523383A patent/JP5230418B2/ja not_active Expired - Fee Related
- 2006-07-28 AU AU2006274866A patent/AU2006274866B2/en not_active Ceased
- 2006-07-28 EA EA200800482A patent/EA014188B1/ru not_active IP Right Cessation
- 2006-07-28 DK DK06764268.6T patent/DK1912981T3/da active
- 2006-07-28 AP AP2008004306A patent/AP2585A/xx active
- 2006-07-28 EP EP06764268A patent/EP1912981B1/en active Active
- 2006-07-28 WO PCT/EP2006/064822 patent/WO2007014927A2/en active Application Filing
- 2006-07-28 UY UY29704A patent/UY29704A1/es unknown
- 2006-07-28 DE DE602006011905T patent/DE602006011905D1/de active Active
- 2006-07-28 AT AT06764268T patent/ATE455775T1/de active
- 2006-07-28 CA CA2617103A patent/CA2617103C/en not_active Expired - Fee Related
- 2006-07-28 SI SI200630627T patent/SI1912981T1/sl unknown
- 2006-07-28 AR ARP060103303A patent/AR057702A1/es not_active Application Discontinuation
- 2006-07-28 BR BRPI0614153-6A patent/BRPI0614153A2/pt not_active Application Discontinuation
- 2006-07-28 MY MYPI20063670 patent/MY151026A/en unknown
- 2006-07-29 SV SV2006002641A patent/SV2008002641A/es unknown
-
2007
- 2007-12-20 IL IL188320A patent/IL188320A/en not_active IP Right Cessation
-
2008
- 2008-02-29 NO NO20081075A patent/NO20081075L/no not_active Application Discontinuation
- 2008-06-20 HK HK08106903.5A patent/HK1116488A1/xx not_active IP Right Cessation
-
2010
- 2010-04-14 HR HR20100209T patent/HRP20100209T1/hr unknown
- 2010-04-20 CY CY20101100355T patent/CY1110008T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100209T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
NO20081071L (no) | Makrocykliske inhibitorer av hepatitt C virus | |
RS51243B (sr) | Inhibitori ns-3 serina hcv proteaze | |
HRP20181075T1 (hr) | Makrociklični inhibitori hepatitisa c serin proteaze | |
JP2013514359A5 (xx) | ||
EP2041159B8 (en) | Macrocyclic compounds as antiviral agents | |
SG161315A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
MY146123A (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatment using the same | |
CU23787B7 (es) | Compuestos macrocíclicos como inhibidores de la replicación viral | |
WO2011041713A3 (en) | Piperazinyl antiviral agents | |
TW200745035A (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
UY28581A1 (es) | Compuestos nucleosidicos para el tratamiento de infecciones virales | |
BR112014000563A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
NO20074613L (no) | Tricykliske nukleosidforbindelser for behandling av virale infeksjoner | |
SG164376A1 (en) | Hcv ns3 protease inhibitors | |
NZ587133A (en) | Macrocyclic serine protease inhibitor compounds for treating an HCV infection | |
TW200602064A (en) | Nucleoside derivatives for treating hepatitis C virus infection | |
TW200639169A (en) | Bicyclic heteroaryl derivatives for treating viruses | |
TW200720285A (en) | Nucleoside compounds for treating viral infections | |
DK1569929T3 (da) | Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner | |
MX337050B (es) | Compuestos 4'-azido-nucleósidos como anti-vhc. | |
UA91255C2 (xx) | Антивірусні нуклеозиди$антивирусные нуклеозиды | |
JP2010521481A5 (xx) | ||
WO2021262826A3 (en) | 1'-cyano nucleoside analogs and uses thereof | |
DE602005018972D1 (de) | 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren |